Biogen | BIIB - 销售和管理费用

金融业

USD

USD 29.48B

现金及等价物

USD 3.38B

USD 797.5M

USD 9.19B

USD 3B

USD 6.56B

USD 514.3M

USD 649.7M

7.61K

EPS每股收益

USD 3.57

股本和储备

USD 18.65B

USD 1.82B

债务利息支出

USD 72.6M

USD 37.9M

USD 6.29B

USD 31.49B

USD 319.5M

USD 1.96B

USD 514.3M

普通股股本

USD 146.7M

13.7

USD 377.7M

USD 2.25B

销售和管理费用

USD 554.3M

USD 1.95B

贸易债权人

USD 358.5M

应收帐款人

USD 1.79B

	销售和管理费用	更改		日
AbbVie	USD 3.58B		316M	2026-03
Acadia Pharmaceuticals	USD 160.79M		14.06M	2026-03
ALKERMES	USD 264.59M		77.4M	2026-03
Amgen	USD 1.58B		354M	2026-03
Bayer	EUR 3.7B		356M	2026-03
Biogen	USD 554.3M		128.2M	2026-03
BioMarin Pharmaceutical	USD 258.28M		63.92M	2026-03
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Eli Lilly	USD 2.93B		198M	2026-03
Esperion Therapeutics	USD 39.42M		456K	2025-12
Gilead Sciences	USD 1.45B		326M	2026-03
Incyte	USD 328.1M		62.31M	2026-03
Merck	USD 2.67B		180M	2026-03
Moderna	USD 173M		135M	2026-03
Neurocrine Biosciences	USD 318.5M		16.7M	2026-03
Novartis	USD 3.14B		296M	2026-03
Pfizer	USD 2.92B		1.16B	2026-03
PTC Therapeutics	USD 73.89M		13.31M	2026-03
Puma Biotechnology	USD 16.82M		8.15M	2024-09
Regeneron Pharmaceuticals	USD 647.7M		127.3M	2026-03
Sangamo BioSciences	USD 9.64M		1.83M	2024-06
Sanofi	EUR 2.33B		419M	2026-03
Sanofi	EUR 2.49B		252M	2026-03
Sarepta Therapeutics	USD 54.03M		51.35M	2026-03
Teva Pharmaceutical Industries	USD 1000M		120M	2026-03
Ultragenyx Pharmaceutical	USD 88M		1000K	2026-03
United Therapeutics	USD 156.6M		34M	2026-03
Vertex Pharmaceuticals	USD 493.7M		6.7M	2026-03